Ann: AGM Presentation, page-26

I am making my opinion going by the growth rate over last 8 months. Despite what management has been telling the adoption has not picked up in the last 2 to 3 qtrs by any significant proportion. Negative cashflow has infact gone much above $1m per quarter. No. of labs using the product has not changed even in existing clients in last 6 months. I am sure BCT has smart people and tech but they seem to be under utilised given it is only one product business. Same issue with sales & marketing team, even after winning the client the adoption of product is very limited. Client Acquisition Cost is in millions if we look at negative cashflow per quarter. For example getting the third pharma has costed more than $2m. Merger with an established player in this space can allow to leverage all these resources. Dyor.